Table 5.
Previous reports on gemcitabine and paclitaxel therapy after failure of cisplatin-based chemotherapy
| Study year (Ref.) | N | Gemcitabine, Paclitaxel (mg/m2; day) (every weeks) | CR/PR (%) | SR 1-yr/2-yr (%) | Median survival (mos) | Grade 3/4 leuko-/thrombocytopenia (%) |
|---|---|---|---|---|---|---|
| 2001 [10] | 41 |
2,500–3,000; 1 150; 1 (2) |
27.5/32.5 | NS/NS | 14.4 | 31.7/0.0 |
| 2001 [11] | 15 |
1,000; 1, 8, 15 200; 1 (3) |
6.7/40.0 | NS/NS | NS | NS/NS |
| 2005 [12] | 36 |
1,000; 1, 8, 15 110; 1, 8, 15 (4) |
41.7/27.8 | NS/NS | 15.3 | 36.1/8.3 |
| 2006 [13] | 23 |
2,500; 1 150; 1 (2) |
0.0/30.4 | NS/NS | 12.1 | 26.1/NS |
| 2006 [14] | 14 |
1,000; 1, 8 175; 1 (3) |
50.0/0.0 | NS/NS | 13 | 35.7/0.0 |
| 13 |
1250; 1 120; 2 (2) |
7.7/30.8 | NS/NS | 9 | 23.1/15.4 | |
| 2007 [15] | 10 |
1,000; 1, 8, 15 200; 1 (3) |
20.0/50.0 | 40/NS | 10.3 | 50.0/10.0 |
| 2008 [16] | 20 |
2,500; 1 150; 1 (2/3) |
5.0/25.0 | 35/NS | 11.5 | 30.0/5.0 |
| 2009 [17] | 33 |
1,000; 1, 8, 15 180; 1 (4) |
3.0/0.0 | NS/NS | 11.3 | 18.2/NS |
| 2011 [18] | 24 |
1,000; 1, 8, 15 200; 1 (3) |
8.3/33.3 | 52/11 | 12.4 | 66.7/4.2 |
| 2011 [19] | 48 |
1,000; 1, 8 175; 1 (3a) |
12.5/25.0 | NS/NS | 7.8 | NS/NS |
|
1000; 1, 8 175; 1 (3b) |
14.6/26.8 | NS/NS | 8.0 | NS/NS | ||
| This study | 35 |
700; 1, 8 70; 1, 8 (4) |
0.0/25.7 | 58.1/32.9 | 12.0 | 14.3/8.6 |
NS not shown, SR survival rate, yr year, mos months
aA maximum of 6 cycles; b Given until disease progression